Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Single-Cell Multi-Ome Analysis Reveals Novel Molecular Mechanisms Underlying Subclonal Response to Survivin Inhibition in Relapsed/Refractory Multiple Myeloma

Atonu Chakrabortty, Harish Kumar, Jeremiah Pfitzer, Neeraj Sharma, Razan Waliagha, Ujjal Mukherjee, Shaji Kunnathu Kumar, Linda Banovic Baughn, Brian Van Ness, Amit K Mitra

Blood (2023) 142 (Supplement 1): 6616.

https://doi.org/10.1182/blood-2023-190442

Published: 2023

Journal Articles

Mutant N- and K- Ras S how Distinct Effects on Growth, Signaling and Drug Response in CRISPR-Cas Edited Alleles of a Myeloma Cell Line

Brian Van Ness, Amit K Mitra, Lisa Wiesen, Linda Banovic Baughn, Shaji Kunnathu Kumar, Joachim Petit, Jeremiah Pfizer, Kelli Gyotoku

Blood (2023) 142 (Supplement 1): 3320.

https://doi.org/10.1182/blood-2023-179579

Published: 2023

Journal Articles

Single-Cell Transcriptomics Identifies Intra-Tumor Heterogeneity in Human Myeloma Cell Lines

Amit Kumar Mitra, PhD, Holly Stessman, PhD, Michael A. Linden, MDPhD, Brian Van Ness, PhD

Blood (2014) 124 (21): 3385.

https://doi.org/10.1182/blood.V124.21.3385.3385

Published: 2014

Journal Articles

Comparative Analysis of in Vitro Chemosensitivity to Four Proteasome Inhibitors in Human Myeloma Cell Lines

Amit Kumar Mitra, PhD, Taylor S Harding, B.A., Brian Van Ness, PhD

Blood (2014) 124 (21): 3436.

https://doi.org/10.1182/blood.V124.21.3436.3436

Published: 2014

Journal Articles

Generation of a Predictive Score for Ixazomib Response in Multiple Myeloma

Amit Kumar Mitra, PhD, Sanjoy Dey, Andrew Hangsleben, Michael Steinbach, Vipin Kumar, PhD, Brian Van Ness, PhD

Blood (2014) 124 (21): 5695.

https://doi.org/10.1182/blood.V124.21.5695.5695

Published: 2014

Journal Articles

Modeling Myeloma Treatment through Epigenetic Modification: Synergistic Combination of EZH2 and Histone Deacetylase Inhibitors

Taylor S Harding, B.A., Jessica Swanson, Brian Van Ness, PhD

Blood (2014) 124 (21): 5719.

https://doi.org/10.1182/blood.V124.21.5719.5719

Published: 2014

Journal Articles

Strategies To Identify Effective Treatments For Proteasome Inhibitor Resistant Multiple Myeloma

Brian Van Ness, Ph.D, Holly A. F. Stessman, Ph.D., Linda B. Baughn, Ph.D., Aatif Mansoor, Amit Mitra, Nathan G. Dolloff, PhD, Chad L. Myers, PhD, Fenghuang Zhan, MD&PhD, Taylor Harding, B.S.

Blood (2013) 122 (21): 278.

https://doi.org/10.1182/blood.V122.21.278.278

Published: 2013

Journal Articles

Low Expression of CXCR4 in Bortezomib-Resistant Multiple Myeloma Correlates with Extramedullary Disease in a Murine Mouse Model

Holly A. F. Stessman, Aatif Mansoor, Fenghuang Zhan, MD, PhD, Guido J. Tricot, MD, PhD, John Sunderland, PhD, Susan A. Walsh, Siegfried Janz, M.D., Brian Van Ness, Ph.D., Linda B. Baughn, Ph.D.

Blood (2012) 120 (21): 442.

https://doi.org/10.1182/blood.V120.21.442.442

Published: 2012

Journal Articles

In Silico Prediction of Novel Drug Combinations to Combat Bortezomib-Resistant Multiple Myeloma

Holly A. F. Stessman, Tian Xia, PhD, Aatif Mansoor, Raamesh Deshpande, Linda B. Baughn, Ph.D., Chad L. Myers, PhD, Nathan G. Dolloff, PhD, Brian Van Ness, Ph.D.

Blood (2012) 120 (21): 1344.

https://doi.org/10.1182/blood.V120.21.1344.1344

Published: 2012

Journal Articles

Expression of Germinal Center B Cell Markers in Bortezomib-Resistant Multiple Myeloma Cells

Holly Stessman, Linda B. Baughn, Ph.D., Aatif Mansoor, Brian Van Ness, Ph.D.

Blood (2011) 118 (21): 129.

https://doi.org/10.1182/blood.V118.21.129.129

Published: 2011

Journal Articles

Modeling Proteasome Inhibition in Lymphoma

Linda B. Baughn, Ph.D., Holly Stessman, Aatif Mansoor, Brian Van Ness, Ph.D.

Blood (2011) 118 (21): 4946.

https://doi.org/10.1182/blood.V118.21.4946.4946

Published: 2011

Journal Articles

Good and Poor Response Gene Expression Signatures to Proteasome Inhibitors Using a Mouse Model of Multiple Myeloma

Holly Stessman, Linda B. Baughn, Ph.D., Aaron G. Sarver, Ph.D., Aatif Mansoor, Tzu G. Wu, Ph.D., Siegfried Janz, M.D., Brian Van Ness, Ph.D.

Blood (2011) 118 (21): 1843.

https://doi.org/10.1182/blood.V118.21.1843.1843

Published: 2011

Journal Articles

Identification of Single Nucleotide Polymorphism Interactions Associated with Survival and Risk In Multiple Myeloma Using Novel Data Mining Methods

Brian Van Ness, Ph.D., Majda Haznadar, Ph.D., Gang Fang, Wen Wang, Vanja Paunic, Michael Steinbach, Vipin Kumar, Ph.D., Patrick Day, Johnson David, Gareth J Morgan, MD, PhD, Bart Barlogie, MD, PhD, Brian GM Durie, MD

Blood (2010) 116 (21): 2973.

https://doi.org/10.1182/blood.V116.21.2973.2973

Published: 2010

Journal Articles

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

David C. Johnson, Sophie Corthals, Christine Ramos, Antje Hoering, Kim Cocks, Nicholas J. Dickens, Jeff Haessler, Harmut Goldschmidt, J. Anthony Child, Sue E. Bell, Graham Jackson, Dalsu Baris, S. Vincent Rajkumar, Faith E. Davies, Brian G. M. Durie, John Crowley, Pieter Sonneveld, Brian Van Ness, Gareth J. Morgan

Blood (2008) 112 (13): 4924–4934.

https://doi.org/10.1182/blood-2008-02-140434

Published: 2008

Includes: Supplemental data

Journal Articles

Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.

Brian G.M. Durie, MD, Brian Van Ness, PhD, Christine Ramos, PhD, Owen Stephens, Majda Haznadar, Antje Hoering, PhD, Jeff Haessler, PhD, Michael S. Katz, BS, Gregory R. Mundy, MD, Robert A. Kyle, MD, Gareth J. Morgan, MD, PhD, John Crowley, PhD, Bart Barlogie, MD, John Shaughnessy, Jr., PhD

Blood (2007) 110 (11): 816.

https://doi.org/10.1182/blood.V110.11.816.816

Published: 2007

Journal Articles

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications

Natalia Gonzalez-Paz, Wee J. Chng, Rebecca F. McClure, Emily Blood, Martin M. Oken, Brian Van Ness, C. David James, Paul J. Kurtin, Kimberly Henderson, Gregory J. Ahmann, Morie Gertz, Martha Lacy, Angela Dispenzieri, Philip R. Greipp, Rafael Fonseca

Blood (2006) 109 (3): 1228–1232.

https://doi.org/10.1182/blood-2006-05-024661

Published: 2006

Journal Articles

SNP Genotypes as Prognostic Factors Associated with Staging in Myeloma: The First Combined SNP Association Analysis of SWOG, ECOG, and MRC Clinical Trials from the Bank on a Cure.

Brian Van Ness, John Crowley, Emily Blood, Erik Rasmussen, Christine Ramos, Suzanne Grindle, Gareth Morgan, David Johnson, Antje Hoering, Philip Greipp, Bart Barlogie, Brian Durie

Blood (2005) 106 (11): 3489.

https://doi.org/10.1182/blood.V106.11.3489.3489

Published: 2005

Journal Articles

Incidence, Outcomes, and SNP Genotypes Show Different Ethnic Association in Patients with Myeloma, Assessed in SWOG and ECOG Clinical Trials S9321 and E9486: From the Bank on a Cure.

Brian Van Ness, John Crowley, Christine Ramos, Suzanne Grindle, Erik Rasmussen, Emily Blood, Antje Hoering, Bart Barlogie, Philip Greipp, Brian Durie

Blood (2005) 106 (11): 506.

https://doi.org/10.1182/blood.V106.11.506.506

Published: 2005

Journal Articles

Associations of DNA Repair Gene Polymorphisms in XRCC1 and ERCC2 with Clinical Outcome in ECOG Trial E9486.

Brian Van Ness, Ph.D., Emily Blood, Ph.D., Philip Greipp, M.D., Neil Kay, M.D., Vincent Rajkumar, M.D., Robert Kyle, M.D., Martin Oken, M.D., Rafael Fonseca, M.D., Fangyi Zhao, Ph.D.

Blood (2004) 104 (11): 1475.

https://doi.org/10.1182/blood.V104.11.1475.1475

Published: 2004

Journal Articles

Genetic Polymorphisms Associated with Clinical Outcome in the Intergroup Trial S9321, Comparing High Dose Therapy with Standard Dose Therapy for Myelomaon, on Behalf of ECOG, SWOG, CALGB, and the Bank on a Cure.

Rafael Santana-Davila, M.D., John Crowley, Ph.D., Brian Durie, M.D., Bart Barlogie, M.D., Philip Greipp, M.D., Brian Van Ness, Ph.D.

Blood (2004) 104 (11): 1495.

https://doi.org/10.1182/blood.V104.11.1495.1495

Published: 2004

NARROW

Single-Cell Multi-Ome Analysis Reveals Novel Molecular Mechanisms Underlying Subclonal Response to Survivin Inhibition in Relapsed/Refractory Multiple Myeloma

Mutant N- and K- Ras S how Distinct Effects on Growth, Signaling and Drug Response in CRISPR-Cas Edited Alleles of a Myeloma Cell Line

Single-Cell Transcriptomics Identifies Intra-Tumor Heterogeneity in Human Myeloma Cell Lines

Comparative Analysis of in Vitro Chemosensitivity to Four Proteasome Inhibitors in Human Myeloma Cell Lines

Generation of a Predictive Score for Ixazomib Response in Multiple Myeloma

Modeling Myeloma Treatment through Epigenetic Modification: Synergistic Combination of EZH2 and Histone Deacetylase Inhibitors

Strategies To Identify Effective Treatments For Proteasome Inhibitor Resistant Multiple Myeloma

Low Expression of CXCR4 in Bortezomib-Resistant Multiple Myeloma Correlates with Extramedullary Disease in a Murine Mouse Model

In Silico Prediction of Novel Drug Combinations to Combat Bortezomib-Resistant Multiple Myeloma

Expression of Germinal Center B Cell Markers in Bortezomib-Resistant Multiple Myeloma Cells

Modeling Proteasome Inhibition in Lymphoma

Good and Poor Response Gene Expression Signatures to Proteasome Inhibitors Using a Mouse Model of Multiple Myeloma

Identification of Single Nucleotide Polymorphism Interactions Associated with Survival and Risk In Multiple Myeloma Using Novel Data Mining Methods

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications

SNP Genotypes as Prognostic Factors Associated with Staging in Myeloma: The First Combined SNP Association Analysis of SWOG, ECOG, and MRC Clinical Trials from the Bank on a Cure.

Incidence, Outcomes, and SNP Genotypes Show Different Ethnic Association in Patients with Myeloma, Assessed in SWOG and ECOG Clinical Trials S9321 and E9486: From the Bank on a Cure.

Associations of DNA Repair Gene Polymorphisms in XRCC1 and ERCC2 with Clinical Outcome in ECOG Trial E9486.

Genetic Polymorphisms Associated with Clinical Outcome in the Intergroup Trial S9321, Comparing High Dose Therapy with Standard Dose Therapy for Myelomaon, on Behalf of ECOG, SWOG, CALGB, and the Bank on a Cure.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only